![]() Infinity Pharmaceuticals Infinity Pharmaceuticals engages in the discovery and development of medicines for the treatment of cancer and related conditions. | ![]() Onconova Therapeutics Onconova Therapeutics is a biopharmaceutical company developing small molecule drug candidates for the treatment of cancer. | Processa Pharmaceuticals Processa Pharmaceuticals (formerly Heatwurx) is a company focused on developing treatments for patients with an unmet medical need. | ![]() HCW Biologics HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction. | |
Founding Date | Founding Date 2000 | Founding Date 1998 | Founding Date 2017 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations Newtown, US HQ Boston, US Newtown, US Pennington, US | Locations Hanover, US HQ | Locations Miramar, US HQ |
Employees | Employees 25 | Employees 1732% decrease | Employees 1033% decrease | Employees 40 |
Valuation ($) | Valuation ($) 726.1 k | Valuation ($) 20.9 m | Valuation ($) 4.4 m | Valuation ($) 16.7 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $2.6m (FY, 2022) | Revenue (est.) $2.8m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $54.2k (FY, 2025) |
Net income | Net income ($44.4m) (FY, 2022) | Net income $9.2m (FY, 2024) | Net income ($13.6m) (FY, 2025) | Net income ($8m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 106.6m | Total funding raised $ 88m | Total funding raised N/A | Total funding raised $ 24.3m |

Onconova Therapeutics is a biopharmaceutical company developing small molecule drug candidates for the treatment of cancer.
View companyProcessa Pharmaceuticals (formerly Heatwurx) is a company focused on developing treatments for patients with an unmet medical need.
View company
HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction.
View company